Optimizing the Treatment Strategy for Age-related Macular Degeneration

NAActive, not recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

May 20, 2020

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2026

Conditions
Wet Macular Degeneration
Interventions
OTHER

Observe and Plan

First the individual interval between the injections of anti-VEGF (vascular endothelial growth factor) is established by observing the time from the loading dose to recurrence of the disease. The patient will come to control every four weeks to establish this interval. Second, the patient will receive injections at intervals that are two weeks shorter than the observed period. 2-3 injections are given before the next control. The control should be no later than six months ahead.

OTHER

Treat-and-Extend

"At the first control 4 weeks after the loading dose, the ophthalmologist assesses whether the macula is still wet or whether the macula is dry. In case of wet macula, the patient receives a new injection on the same day and a new control in 4 weeks. If the macula is dry, the patient will return in 2 weeks for the next injection, ie the injection interval is extended from 4 to 6 weeks.~Patients will be controlled every time they are to receive an intravitreal injection. If the macula is dry, the injection interval will be extended by 2 weeks and if the macula is wet the interval is shortened by 2 weeks. The shortest interval will be 4 weeks."

Trial Locations (3)

Unknown

Ålesund Hospital, Ålesund

Molde Hospital, Molde

N-7006

Dept. of Ophthalmology, St Olavs Hospital, Trondheim University Hospital, Trondheim

All Listed Sponsors
collaborator

Norwegian University of Science and Technology

OTHER

collaborator

Molde Hospital

OTHER

collaborator

Alesund Hospital

OTHER

lead

St. Olavs Hospital

OTHER